Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      ADAMA Reports Second Quarter and First Half 2022 Results

      ADAMA Logo

      News provided by

      ADAMA Ltd.

      Aug 29, 2022, 07:20 ET

      Share this article

      Share this article


      Continued strong momentum as record top line results are translated into bottom line income

      Second Quarter 2022 Highlights:

      • Sales up 21% to an all-time quarterly record-high of $1,479 million (+24% in RMB terms; +25% in CER[1] terms), driven by 22% higher prices and 3% volume growth
      • Improvement of Opex/Sales ratio of 18.1% vs. 19.7% in Q2 2021
      • Adjusted EBITDA up 29% to $240 million (RMB: +32%), representing an improvement of EBITDA margin from 15.2% in Q2 2021 to 16.2% in Q2 2022
      • Adjusted net income up 20% to $76 million; Reported net income up 36% to $46 million (RMB: +39%)

      First Half 2022 Highlights

      • Sales up 24% to an all-time half-year record-high of $2,899 million (+25% in RMB terms; +28% in CER terms), driven by 20% higher prices and 8% volume growth
      • Improvement of Opex/Sales ratio of 18.9% vs. 19.9% in H1 2021
      • Adjusted EBITDA up 29% to $441 million (RMB: +29%), representing an improvement of EBITDA margin from 14.7% in H1 2021 to 15.2% in H1 2022
      • Adjusted net income up 31% to $151 million; Reported net income up 100% to $113 million (RMB: +99%)

      BEIJING and TEL AVIV, Israel, Aug. 29, 2022 /PRNewswire/ -- ADAMA Ltd. (the "Company") (SZSE: 000553), today reported its financial results for the second quarter and six-month period ended June 30, 2022.

      Ignacio Dominguez, President and CEO of ADAMA, said, "ADAMA delivers another strong record quarter and half year period, with continued top line growth translating into bottom line value. Farmer fundamentals continue to be positive as crop commodity prices remain elevated, despite some easing of prices towards the end of the quarter, currently driving the demand for crop protection products.

      "In a world of surmounting challenges, ADAMA is committed to providing farmers with the solutions they need and want for feeding the world, while continuously introducing to the market new products with unique ADAMA added value formulation technologies."

      Table 1. Financial Performance Summary

      USD (m)

      As Reported

      Adjustments

      Adjusted

      Q2

      2022

      Q2

      2021

      % Change

      Q2

      2022

      Q2

      2021

      Q2

      2022

      Q2

      2021

      % Change

      Revenues

      1,479

      1,220

      +21 %

      -

      -

      1,479

      1,220

      +21 %

      Gross profit

      386

      340

      +13 %

      52

      25

      437

      365

      +20 %

      % of sales

      26.1 %

      27.9 %




      29.6 %

      29.9 %


      Operating income (EBIT)

      143

      90

      +58 %

      27

      35

      170

      125

      +36 %

      % of sales

      9.6 %

      7.4 %




      11.5 %

      10.3 %


      Income before taxes

      57

      36

      +59 %

      31

      35

      88

      71

      +24 %

      % of sales

      3.9 %

      3.0 %




      6.0 %

      5.8 %


      Net income

      46

      34

      +36 %

      30

      30

      76

      63

      +20 %

      % of sales

      3.1 %

      2.8 %




      5.1 %

      5.2 %


      EPS









      - USD

      0.0198

      0.0145




      0.0326

      0.0272


      - RMB

      0.1307

      0.0938




      0.2152

      0.1759


      EBITDA

      224

      164

      +36 %

      16

      21

      240

      186

      +29 %

      % of sales

      15.1 %

      13.5 %




      16.2 %

      15.2 %












      USD (m)

      As Reported

      Adjustments

      Adjusted

      H1

      2022

      H1

      2021

      % Change

      H1

      2022

      H1

      2021

      H1

      2022

      H1

      2021

      % Change

      Revenues

      2,899

      2,329

      +24 %

      -

      -

      2,899

      2,329

      +24 %

      Gross profit

      746

      645

      +16 %

      106

      42

      852

      687

      +24 %

      % of sales

      25.7 %

      27.7 %




      29.4 %

      29.5 %


      Operating income (EBIT)

      267

      156

      +72 %

      36

      68

      303

      223

      +36 %

      % of sales

      9.2 %

      6.7 %




      10.4 %

      9.6 %


      Income before taxes

      129

      65

      +98 %

      40

      68

      168

      133

      +27 %

      % of sales

      4.4 %

      2.8 %




      5.8 %

      5.7 %


      Net income

      113

      57

      +100 %

      37

      59

      151

      115

      +31 %

      % of sales

      3.9 %

      2.4 %




      5.2 %

      5.0 %


      EPS









      - USD

      0.0487

      0.0244




      0.0648

      0.0496


      - RMB

      0.3142

      0.1575




      0.4197

      0.3207


      EBITDA

      427

      302

      +42 %

      14

      41

      441

      343

      +29 %

      % of sales

      14.7 %

      13.0 %




      15.2 %

      14.7 %












      Notes:

      "As Reported" denotes the Company's financial statements according to the Accounting Standards for Business Enterprises and the implementation guidance, interpretations and other relevant provisions issued or revised subsequently by the Chinese Ministry of Finance (the "MoF) (collectively referred to as "ASBE"). Note that in the reported financial statements, as a result of recent changes in the ASBE guidelines [IAS 37], certain items as of Q4 2021 (specifically certain transportation costs and certain idleness charges) have been reclassified from Operating Expenses to COGS. Please see the appendix to this release for further information.

      Relevant income statement items contained in this release are also presented on an "Adjusted" basis, which exclude items that are of a transitory or non-cash/non-operational nature that do not impact the ongoing performance of the business, and reflect the way the Company's management and the Board of Directors view the performance of the Company internally. The Company believes that excluding the effects of these items from its operating results allows management and investors to effectively compare the true underlying financial performance of its business from period to period and against its global peers. A detailed summary of these adjustments appears in the appendix below.

      The number of shares used to calculate both basic and diluted earnings per share in both Q2 and H1 2021 is 2,329.8 million shares. The number of shares used to calculate both basic and diluted earnings per share in both Q2 and H1 2022 is 2,329.8 million shares.

      The general crop protection market environment[2] 

      Crop prices remain elevated above historic averages despite decreasing somewhat in Q2 2022 after reaching historically high levels in Q1 2022. Prices are, however, expected to remain elevated into H2 2022 and beyond, supported by key fundamentals including very low stocks, unfavorable weather conditions in the Americas and parts of Europe and continued supply and logistics disruptions exacerbated by the conflict in Ukraine.

      The high crop prices incentivize another year of increases in global planted areas. As a result, the global demand for crop protection remains strong as farmers strive to maximize yields in this high crop price environment. Farmers continue to face high production costs, mainly from higher fertilizer prices resulting from disruption to supply and tight availability caused by the conflict in Ukraine, yet their farming activities are nevertheless still very profitable in most regions.

      Global energy prices remain inflated while the challenging cost environment is expected to extend throughout 2022. Despite this, global energy prices have decreased recently mainly due to concerns regarding recession, but are expected to remain elevated into H2 2022, due to tight supply and concerns regarding supply outages following sanctions on Russian energy exports combined with pockets of increased demand as economies recover from COVID.

      Global freight and logistics costs are declining as a result of reduced demand in light of COVID lockdowns in China as well as high inflation rates, but remain high after reaching record highs in February 2022. Prices are expected to remain elevated well into H2 2022, due to high fuel costs, prolonged supply chain disruptions while the availability of shipping resources continues to be limited. Additionally, global freight volumes are expected to increase as the lockdown in Shanghai Port has eased and production has resumed.

      Despite some easing in global procurement prices for raw materials, intermediates and active ingredients during the quarter, most products are expected to keep fluctuating at elevated levels in H2 2022. This overall trend is impacted both by the general softening of prices in China and by the increase in prices of such products in other geographies. In China, an increase in production capacity and an ease in logistic disruptions led to softening of prices, while in other geographies cost inflation, energy prices, supply shortages and logistic challenges are driving prices upward and impacting availability. With strong global crop protection demand, transportation disruptions and supply shortages driven by the ongoing conflict in Ukraine, as well as the "Zero COVID" policy in China, prices are expected to remain high. 

      Portfolio Development Update

      During the second quarter of 2022 ADAMA continued to register and launch multiple new products in markets across the globe, adding on to its differentiated product portfolio. Differentiated products include a variety of product characteristics and may include products with (i) unique proprietary formulations, (ii) products with more than one mode of action, (iii) recently off-patented active ingredients (AI's) that have been classified as high commercial potential - "Core Leap" AI's and (iv) biologicals. Among these were:

      • Launch of Novali® in Australia, a herbicide for use in grasses on cereals and pulses, containing Pyroxasulfone, a "Core Leap" AI produced in-house by ADAMA.
      • Registration of Nimitz® in South Africa, an innovative nematicide for potatoes containing proprietary AI Fluensulfone.
      • Registration of Jumbo® in Brazil, a dual mode broad spectrum herbicide for all year-round use in sugarcane.
      • Launch in Brazil of Cheval®, a premium dual mode pre-seed and post-emergent herbicide, powered by ADAMA's proprietary T.O.V. Formulation Technology, for use in soybean and other crops.
      • Initiation of in-house production of "Core Leap" AI, Indoxacarb, through a new proprietary synthesis process.
      • Launch of Suprado™ for the Consumer and Professional sector in the US, an insecticide with a unique mode-of-action for the treatment of Annual Bluegrass weevil on turf powered by ADAMA's proprietary AI Novaluron.
      • Registration in France of Goltix® Silver, a dual mode herbicide for sugar beets.
      • Registration in Guatemala of Expert Grow®, a triple mode-of-action bio-stimulant for the increase of yield in a variety of F&V (fruit & vegetables) as well as in Soybean, based on a unique fermentation process developed by ADAMA improving the plant's photosynthetic thereby reducing abiotic stress, improving fruit/pod retention and plant growth. This product complements LATAM's sustainable offering of biological products and is expected to be rolled-out to additional key countries in the region in coming years.

      Financial Highlights

      Revenues in the second quarter grew by 21% (+24% in RMB terms; +25% in CER terms) to $1,479 million, driven by a significant 22% increase in prices, a trend which started in the third quarter of 2021. The markedly higher prices were complemented by continued volume growth (+3%), including the contribution of a newly acquired company, achieved despite supply challenges in the market, and the adverse impact of exchange rate movements.

      The accelerated growth in the quarter brought half-year sales to a record-high of $2,899 million, an increase of 24% (+25% in RMB terms; +28% in CER terms) driven by a 20% increase in prices and an 8% growth in volume.

      Table 2. Regional Sales Performance



      Q2 2022

      $m

      Q2 2021

      $m

      Change

      USD

      Change

      CER


      H1 2022

      $m

      H1 2021

      $m

      Change

      USD

      Change

      CER

      Europe


      293

      261

      12.4 %

      20.9 %


      650

      605

      7.4 %

      12.2 %

      North America


      278

      256

      8.3 %

      8.5 %


      562

      445

      26.1 %

      26.0 %

      Latin America


      379

      271

      39.9 %

      35.0 %


      613

      449

      37.0 %

      33.6 %

      Asia Pacific


      332

      242

      37.3 %

      42.5 %


      720

      483

      49.1 %

      52.6 %

       Of which China


      213

      135

      57.2 %

      60.2 %


      449

      259

      73.2 %

      73.4 %

      India, Middle East & Africa


      197

      190

      4.0 %

      15.4 %


      354

      347

      2.0 %

      15.6 %

      Total


      1,479

      1,220

      21.3 %

      24.8 %


      2,899

      2,329

      24.5 %

      27.9 %

      Europe:

      In Europe, the Company presented strong sales, despite the negative impact of exchange rates, loss of sales due to the Ukraine-Russia conflict and some supply challenges. The Company continued to gain market share in the key countries France and Italy, presenting strong sales across most countries in the region and particularly in France, Germany, Hungary as well as in Scandinavian, BENELUX, Baltic and Balkan countries, while negative seasonal conditions impacted the sales in Spain and Italy.

      Notably, the Company benefited from the sale of Folpet in Germany, which was granted an emergency registration[3] in Barley for 2022.

      North America:

      In the US Ag market, sales increased as the Company focused on the quality of business and despite drought conditions across western Texas and California that impacted demand.

      Very strong growth in sales and gain of market share in Canada due to seizing market opportunity to supply increased demand for cereal herbicides in light of general market supply shortages. ADAMA initiated in-house production of cereal herbicide MCPA to meet this demand.  

      The Consumer & Professional business presented very strong sales achieved through capturing market opportunities and driven by steady demand mainly attributed to the commercial business (hotels, restaurants, etc…) coming back to full strength after COVID shutdowns as well as very successful new launch of Suprado, strengthening ADAMA's position as an innovator in the C&P arena. This is despite softening of demand in the consumer market and with homeowners as inflation rises and recreational activities decrease post-COVID.

      Latin America: 

      Significant growth in sales in Brazil as ADAMA continues to reinforce its position in this market while demand remains strong supported by elevated crop commodities prices.

      The Company's innovative herbicides Araddo®, Cheval® and Arremate® and fungicides Armero™ and Across® continued to be well received in the market.

      Higher sales were also achieved in other LATAM countries, particularly in the key countries Colombia, Argentina and Mexico, despite some supply challenges. 

      Asia-Pacific: The Company's strong growth in Asia Pacific was led by the exceptionally strong sales of raw material, intermediates and fine chemicals in China, driven both by volumes and prices, in light of the strong global demand for crop protection and achieved despite logistic challenges related to COVID. The sales in China of ADAMA's branded portfolio also grew significantly as the Company gains market share, despite the negative impact of some seasonal conditions and the strong competition in the market. 

      In the wider APAC region, strong sales were delivered in the Pacific region, which continued to benefit from the favorable La Niña season, that has now potentially ended after an extended two-year season.

      India, Middle East & Africa: The growth in sales was mainly led by Turkey and Israel following favorable weather conditions and was negatively impacted by the depreciation of the Turkish Lira and by a decline in sales in India.

      Gross Profit reported in the second quarter was up 13% to $386 million (gross margin of 26.1%) compared to $340 million (gross margin of 27.9%) in the same quarter last year and was up 16% to $746 million (gross margin of 25.7%) in the half year period compared to $645 million (gross margin of 27.7%) last year.

      Adjustments to reported results: The adjusted gross profit includes all idleness costs and excludes transportation costs to third parties and its marketing subsidiaries (classified under operating expenses).

      In the reported results, as of Q4 2021, following recent changes in the guidelines in China, the aforementioned transportations costs and OPEX idleness have been reclassified from operating expenses to costs of goods (not impacting the operating results), while these expenses were not recorded in the cost of goods in the second quarter and first half period in 2021, but rather in the operating expenses.

      Additionally, certain extraordinary charges related largely to a temporary disruption of the production of certain products, were adjusted in the second quarter and first half period in 2021. These charges have significantly declined since the first quarter of 2022, as the relocation and upgrade of the manufacturing Jingzhou site in China has been completed and is now at a high level of operation. 

      Excluding the impact of the abovementioned extraordinary items, adjusted gross profit in the second quarter was up 20% to $437 million (gross margin of 29.6%) compared to $365 million (gross margin of 29.9%) in the same quarter last year and was up 24% to $852 million (gross margin of 29.4%) in the half year period compared to $687 million (gross margin of 29.5%) last year.

      In the quarter and half year period, the significantly higher gross profit and improvement in the adjusted gross margin were mainly driven by the markedly higher prices, complemented by continued volume growth, which more than offset higher logistics, procurement and production costs as well as the negative impact of exchange rates.

      Operating expenses reported in the second quarter were $243 million (16.4% of sales) and $479 million (16.5% of sales) in the half year period, compared to $250 million (20.5% of sales) and $489 million (21.0% of sales) in the corresponding periods last year, respectively.

      Adjustments to reported results: please refer to the explanation regarding adjustments to the gross profit in respect to certain transportation costs and idleness.

      Additionally, the Company recorded certain non-operational charges within its reported operating expenses amounting to $22 million in Q2 2022 in comparison to $10 million in Q2 2021 and $28 in H1 2022 in comparison to $26 in H1 2021. These charges include mainly (i) non-cash amortization charges in respect of Transfer assets received from Syngenta related to the 2017 ChemChina-Syngenta acquisition, (ii) charges related to the non-cash amortization of intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions, with no impact on the ongoing performance of the companies acquired and (iii) incentive plans - share-based compensation. For further details on these non-operational charges, please see the appendix to this release.

      Excluding the impact of the abovementioned non-operational charges, adjusted operating expenses in the quarter and half year period were $268 million (18.1% of sales) and $549 million (18.9% of sales), compared to $240 million (19.7% of sales) and $463 million (19.9% of sales) in the corresponding periods last year, respectively.

      The higher operating expenses in the quarter and half-year period reflect the strong growth of the business, an increase in expenses attributed to company success-based employee compensation, higher transportation and logistics costs driven by both an increase in freight costs and volumes transported, the inclusion of a recent acquisition and moderated by the positive impact of exchange rates.

      In addition, in the first quarter the Company recorded a doubtful debt provision for trade receivables in Ukraine.

      Operating income reported in the second quarter was up 58% to $143 million (9.6% of sales) compared to $90 million (7.4% of sales) in the same quarter last year and was up 72% to $267 million (9.2% of sales) in the half year period compared to $156 million (6.7% of sales) last year.

      Excluding the impact of the abovementioned non-operational items, adjusted operating income in the second quarter was up 36% to $170 million (11.5% of sales) compared to $125 million (10.3% of sales) in the same quarter last year and was up 36% to $303 million (10.4% of sales) in the half year period compared to $223 million (9.6% of sales) in the same period last year.

      EBITDA reported in the second quarter was up 36% to $224 million (15.1% of sales) compared to $164 million (13.5% of sales) in the same quarter last year and was up 42% to $427 million (14.7% of sales) in the half year period compared to $302 million (13.0% of sales) last year.

      Excluding the impact of the abovementioned non-operational items, adjusted EBITDA in the second quarter was up 29% to $240 million (16.2% of sales) compared to $186 million (15.2% of sales) in the same quarter last year and was up 29% to $441 million (15.2% of sales) in the half year period compared to $343 million (14.7% of sales) last year.

      Financial expenses and investment income were $82 million in the second quarter and $134 million in the half year period, compared to $54 million and $91 million in the corresponding periods last year, respectively. The higher financial expenses were mainly driven by the net effect of the high Israeli CPI on the ILS-denominated, CPI-linked bonds, higher hedging costs on exchange rates and the valuation of put options attributed to minority stakes.

      Taxes on income in the second quarter were $12 million and $18 million in the half year period, compared to $7 million and $16 million in the corresponding periods last year, respectively.

      Net income attributable to the shareholders of the Company reported in the second quarter was $46 million (3.1% of sales) and $113 million (3.9% of sales) in the half-year period, compared to $34 million (2.8% of sales) and $57 million (2.4% of sales) in the corresponding periods last year, respectively.

      Excluding the impact of the abovementioned extraordinary and non-operational charges, adjusted net income in the second quarter was $76 million (5.1% of sales), and $151 million (5.2% of sales) in the half-year period, compared to $63 million (5.2% of sales) and $115 million (5.0% of sales) in the corresponding periods last year, respectively.

      Trade working capital as of June 30, 2022, was $2,664 million compared to $2,499 million at the same point last year. The increase in working capital was due to an increase in the value and levels of inventory held by the Company to support expected future sales, in light of anticipated supply shortages, logistic challenges and inventory costs increases. This increase in inventory levels was moderated by higher trade payables. Trade receivables increased only slightly in comparison to the growth in sales reflecting good collections across the board.

      The trade capital/last twelve months sales ratio of 49.5% as of June 30, 2022, in comparison to 56.2%, as of June 30, 2021, demonstrates the improved efficiency in the Company's management of its working capital.

      Cash Flow: Operating cash flow of $71 million was generated in the quarter and $215 million consumed in the half year period, compared to $361 million and $231 million generated in the corresponding periods last year, respectively. The lower cash flow generated in the quarter was primarily due to an increase in payments for goods procured in previous quarters supporting the increase in inventory levels.

      Net cash used in investing activities was $107 million in the quarter and $197 million in the first half period, compared to $184 million and $292 million in the corresponding periods last year, respectively. The cash used in investing activities in the second quarter of 2022 and the half year period is largely related to investments in "Core Leap" manufacturing capabilities in Israel and Brazil as well as investments in intangible assets relating to ADAMA's global registrations. In the corresponding periods in 2021, cash was also used for the completion of the payment related to the acquisition of Huifeng's domestic commercial crop protection business and the acquisition of the Huifeng Dafeng manufacturing site towards the end of the second quarter in 2021, as well as for the relocation and upgrade of the manufacturing Sanonda Jingzhou site, which was completed towards the end of the second quarter of 2021.

      Free cash flow of $83 million was consumed in the second quarter and $469 million consumed in the half-year period compared to $132 million generated and $116 million consumed in the corresponding periods last year, respectively, reflecting the aforementioned operating and investing cash flow dynamics.

      Table 3. Revenues by operating segment 

      Sales by segment


      Q2 2022

      USD (m)

      %

      Q2 2021

      USD (m)

      %

      H1 2022

      USD (m)

      %

      H1 2021

      USD (m)

      %

      Crop Protection

      1,327

      89.7 %

      1,104

      90.5 %

      2,598

      89.6 %

      2,111

      90.7 %

      Intermediates and Ingredients

      152

      10.3 %

      116

      9.5 %

      301

      10.4 %

      218

      9.3 %

      Total

      1,479

      100 %

      1,220

      100.0 %

      2,899

      100.0 %

      2,329

      100.0 %

      Sales by product category


      Q2 2022

      USD (m)

      %

      Q2 2021

      USD (m)

      %

      H1 2022

      USD (m)

      %

      H1 2021

      USD (m)

      %

      Herbicides

      702

      47.4 %

      473

      38.7 %

      1,362

      47.0 %

      947

      40.8 %

      Insecticides

      393

      26.6 %

      393

      32.2 %

      743

      25.6 %

      706

      30.3 %

      Fungicides

      232

      15.7 %

      239

      19.6 %

      493

      17.0 %

      455

      19.5 %

      Intermediates and Ingredients

      152

      10.3 %

      116

      9.5 %

      301

      10.4 %

      218

      9.3 %

      Total

      1,479

      100 %

      1,220

      100.0 %

      2,899

      100.0 %

      2,329

      100.0 %

      Note: the sales split by product category is provided for convenience purposes only and is not representative of the way the Company is managed or in which it makes its operational decisions.

      Further Information

      All filings of the Company, together with a presentation of the key financial highlights of the period, can be accessed through the Company website at www.adama.com.

      About ADAMA

      ADAMA Ltd. is a global leader in crop protection, providing solutions to farmers across the world to combat weeds, insects and disease. ADAMA has one of the widest and most diverse portfolios of active ingredients in the world, state-of-the art R&D, manufacturing and formulation facilities, together with a culture that empowers our people in markets around the world to listen to farmers and ideate from the field. This uniquely positions ADAMA to offer a vast array of distinctive mixtures, formulations and high-quality differentiated products, delivering solutions that meet local farmer and customer needs in over 100 countries globally. For more information, visit us at www.ADAMA.com and follow us on Twitter® at @ADAMAAgri.

      Contact

      Rivka Neufeld                                           

      Zhujun Wang

      Global Investor Relations                         

      China Investor Relations

      Email: [email protected]                             

      Email: [email protected] 

      Abridged Adjusted Consolidated Financial Statements

      The following abridged consolidated financial statements and notes have been prepared as described in Note 1 in this appendix. While prepared based on the principles of Chinese Accounting Standards (ASBE), they do not contain all of the information which either ASBE or IFRS would require for a complete set of financial statements, and should be read in conjunction with the consolidated financial statements of both ADAMA Ltd. and Adama Agricultural Solutions Ltd. as filed with the Shenzhen and Tel Aviv Stock Exchanges, respectively.

      Relevant income statement items contained in this release are also presented on an "Adjusted" basis, which exclude items that are of a one-time or non-cash/non-operational nature that do not impact the ongoing performance of the business, and reflect the way the Company's management and the Board of Directors view the performance of the Company internally. The Company believes that excluding the effects of these items from its operating results allows management and investors to effectively compare the true underlying financial performance of its business from period to period and against its global peers.

      Abridged Consolidated Income Statement for the Second Quarter

      Adjusted[4]

      Q2 2022

      USD (m)

      Q2 2021

      USD (m)

      Q2 2022

      RMB (m)

      Q2 2021

      RMB (m)

      Revenues

      1,479

      1,220

      9,780

      7,877

      Cost of Sales

      1,012

      848

      6,693

      5,474

      Other costs

      29

      7

      194

      45

      Gross profit

      437

      365

      2,893

      2,358

      % of revenue

      29.6 %

      29.9 %

      29.6 %

      29.9 %

      Selling & Distribution expenses

      209

      186

      1,383

      1,198

      General & Administrative expenses

      47

      39

      309

      251

      Research & Development expenses

      22

      18

      143

      117

      Other operating expenses

      (10)

      )3)

      (66)

      (17)

      Total operating expenses

      268

      240

      1,770

      1,549

      % of revenue

      18.1 %

      19.7 %

      18.1 %

      19.7 %

      Operating income (EBIT)

      170

      125

      1,123

      809

      % of revenue

      11.5 %

      10.3 %

      11.5 %

      10.3 %

      Financial expenses and investment income

      82

      54

      540

      350

      Income before taxes

      88

      71

      583

      459

      Taxes on Income

      12

      7

      82

      47

      Net Income

      76

      64

      501

      412

      Attributable to:





      Non-controlling interest

      0

      1

      0

      2

      Shareholders of the Company

      76

      63

      501

      410

      % of revenue

      5.1 %

      5.2 %

      5.1 %

      5.2 %

      Adjustments

      30

      30

      197

      192

      Reported Net income attributable to the shareholders of the Company

      46

      34

      304

      218

      % of revenue

      3.1 %

      2.8 %

      3.1 %

      2.8 %

      Adjusted EBITDA

      240

      186

      1,585

      1,199

      % of revenue

      16.2 %

      15.2 %

      16.2 %

      15.2 %

      Adjusted EPS[5]          – Basic

      0.0326

      0.0274

      0.2152

      0.1759

                                            – Diluted

      0.0326

      0.0274

      0.2152

      0.1759

      Reported EPS2            – Basic

      0.0198

      0.0145

      0.1307

      0.0938

                                            – Diluted

      0.0198

      0.0145

      0.1307

      0.0938

      Abridged Consolidated Income Statement for the First Half

      Adjusted[6]

      H1 2022

      USD (m)

      H1 2021

      USD (m)

      H1 2022

      RMB (m)

      H1 2021

      RMB (m)

      Revenues

      2,899

      2,329

      18,796

      15,064

      Cost of Sales

      2,002

      1,630

      12,975

      10,543

      Other costs

      46

      12

      299

      78

      Gross profit

      852

      687

      5,522

      4,443

      % of revenue

      29.4 %

      29.5 %

      29.4 %

      29.5 %

      Selling & Distribution expenses

      408

      364

      2,646

      2,354

      General & Administrative expenses

      93

      71

      606

      459

      Research & Development expenses

      42

      35

      274

      227

      Other operating expenses

      5

      (7)

      29

      (42)

      Total operating expenses

      549

      463

      3,555

      2,998

      % of revenue

      18.9 %

      19.9 %

      18.9 %

      19.9 %

      Operating income (EBIT)

      303

      223

      1,967

      1,445

      % of revenue

      10.4 %

      9.6 %

      10.5 %

      9.6 %

      Financial expenses and investment income

      134

      91

      875

      586

      Income before taxes

      168

      133

      1,092

      859

      Taxes on Income

      18

      16

      115

      105

      Net Income

      151

      117

      978

      754

      Attributable to:





      Non-controlling interest

      0

      2

      0

      7

      Shareholders of the Company

      151

      115

      978

      747

      % of revenue

      5.2 %

      5.0 %

      5.2 %

      5.0 %

      Adjustments

      37

      59

      246

      380

      Reported Net income attributable to the shareholders of the Company

      113

      57

      732

      367

      % of revenue

      3.9 %

      2.4 %

      3.9 %

      2.4 %

      Adjusted EBITDA

      441

      343

      2,862

      2,216

      % of revenue

      15.2 %

      14.7 %

      15.2 %

      14.7 %

      Adjusted EPS[7]        – Basic

      0.0648

      0.0496

      0.4197

      0.3207

                                          – Diluted

      0.0648

      0.0496

      0.4197

      0.3207

      Reported EPS2          – Basic

      0.0487

      0.0244

      0.3142

      0.1575

                                          – Diluted

      0.0487

      0.0244

      0.3142

      0.1575

      Abridged Consolidated Balance Sheet


      June 30

      2022

      USD (m)

      June 30

      2021

      USD (m)

      June 30

      2022

      RMB (m)

      June 30

      2021

      RMB (m)

      Assets





      Current assets:





      Cash at bank and on hand

      491

      717

      3,297

      4,633

      Bills and accounts receivable

      1,606

      1,570

      10,780

      10,144

      Inventories

      2,320

      1,746

      15,569

      11,281

      Other current assets, receivables and prepaid expenses

      351

      323

      2,357

      2,088

      Total current assets

      4,768

      4,357

      32,003

      28,146

      Non-current assets:





      Fixed assets, net

      1,674

      1,472

      11,234

      9,508

      Rights of use assets

      72

      78

      486

      506

      Intangible assets, net

      1,488

      1,509

      9,984

      9,751

      Deferred tax assets

      160

      145

      1,073

      940

      Other non-current assets

      109

      93

      730

      600

      Total non-current assets

      3,503

      3,298

      23,507

      21,304

      Total assets

      8,271

      7,655

      55,510

      49,450






      Liabilities





      Current liabilities:





      Loans and credit from banks and other lenders

      488

      457

      3,273

      2,954

      Bills and accounts payable

      1,271

      833

      8,528

      5,383

      Other current liabilities

      855

      823

      5,739

      5,314

      Total current liabilities

      2,614

      2,113

      17,540

      13,651

      Long-term liabilities:





      Loans and credit from banks and other lenders

      640

      506

      4,292

      3,272

      Debentures

      1,120

      1,238

      7,517

      7,996

      Deferred tax liabilities

      58

      56

      392

      363

      Employee benefits

      115

      116

      769

      748

      Other long-term liabilities

      367

      308

      2,463

      1,989

      Total long-term liabilities

      2,299

      2,224

      15,433

      14,367

      Total liabilities

      4,913

      4,337

      32,973

      28,018






      Equity





      Total equity

      3,358

      3,318

      22,537

      21,432






      Total liabilities and equity

      8,271

      7,655

      55,510

      49,450

      Abridged Consolidated Cash Flow Statement for the Second Quarter


      Q2 2022
      USD (m)

      Q2 2021
      USD (m)

      Q2 2022
      RMB (m)

      Q2 2021
      RMB (m)

      Cash flow from operating activities:





      Cash flow from operating activities

      71

      361

      468

      2,329

      Cash flow from operating activities

      71

      361

      468

      2,329






      Investing activities:





      Acquisitions of fixed and intangible assets

      (107)

      (91)

      (707)

      (591)

      Proceeds from disposal of fixed and intangible assets

      10

      2

      67

      10

      Acquisition of subsidiaries

      0

      (93)

      -

      (600)

      Other investing activities

      (10)

      (1)

      (65)

      (7)

      Cash flow used for investing activities

      (107)

      (184)

      (705)

      (1,188)






      Financing activities:





      Receipt of loans from banks and other lenders

      222

      296

      1,466

      1,915

      Repayment of loans from banks and other lenders

      (150)

      (323)

      (992)

      (2,085)

      Interest payment and other

      (53)

      (50)

      (353)

      (325)

      Dividends to shareholders

      (3)

      -

      (19)

      -

      Other financing activities

      (79)

      22

      (523)

      123

      Cash flow from (used for) financing activities

      (64)

      (58)

      (421)

      (372)

      Effects of exchange rate movement on cash and cash equivalents

      (4)

      3

      174

      (47)

      Net change in cash and cash equivalents

      (103)

      122

      (484)

      723

      Cash and cash equivalents at the beginning of the period

      579

      592

      3,674

      3,892

      Cash and cash equivalents at the end of the period

      475

      714

      3,191

      4,615






      Free Cash Flow

      (83)

      132

      (551)

      854

      Abridged Consolidated Cash Flow Statement for the First Half


      H1 2022
      USD (m)

      H1 2021
      USD (m)

      H1 2022
      RMB (m)

      H1 2021
      RMB (m)

      Cash flow from operating activities:





      Cash flow from operating activities

      (215)

      231

      (1,346)

      1,491

      Cash flow from operating activities

      (215)

      231

      (1,346)

      1,491






      Investing activities:





      Acquisitions of fixed and intangible assets

      (199)

      (182)

      (1,292)

      (1,179)

      Proceeds from disposal of fixed and intangible assets

      11

      3

      70

      20

      Acquisition of subsidiaries

      0

      (101)

      -

      (655)

      Other investing activities

      (9)

      (12)

      (57)

      (77)

      Cash flow used for investing activities

      (197)

      (292)

      (1,279)

      (1,892)






      Financing activities:





      Receipt of loans from banks and other lenders

      374

      584

      2,435

      3,776

      Repayment of loans from banks and other lenders

      (177)

      (360)

      (1,164)

      (2,329)

      Interest payment and other

      (63)

      (60)

      (413)

      (388)

      Dividends to shareholders

      (3)

      -

      (19)

      -

      Other financing activities

      (144)

      22

      (934)

      149

      Cash flow from (used for) financing activities

      (12)

      186

      (94)

      1,209

      Effects of exchange rate movement on cash and cash equivalents

      (4)

      2

      150

      (29)

      Net change in cash and cash equivalents

      (428)

      127

      (2,569)

      780

      Cash and cash equivalents at the beginning of the period

      903

      588

      5,759

      3,835

      Cash and cash equivalents at the end of the period

      475

      714

      3,191

      4,615






      Free Cash Flow

      (469)

      (115)

      (2,999)

      (752)

      Notes to Abridged Consolidated Financial Statements

      Note 1: Basis of preparation

      Basis of presentation and accounting policies: The abridged consolidated financial statements for the quarters ended June 30, 2022 and 2021 incorporate the financial statements of ADAMA Ltd. and of all of its subsidiaries (the "Company"), including Adama Agricultural Solutions Ltd. ("Solutions") and its subsidiaries.

      The Company has adopted the Accounting Standards for Business Enterprises (ASBE) issued by the Ministry of Finance (the "MoF") and the implementation guidance, interpretations and other relevant provisions issued or revised subsequently by the MoF (collectively referred to as "ASBE"). Note that in the reported financial statements, as a result of recent changes in the ASBE guidelines (IAS 37), certain items as of Q4 2021 (specifically certain transportation costs and certain idleness charges) have been reclassified from Operating Expenses to COGS. See the notes to the financial statements for more details in this regard.

      The abridged consolidated financial statements contained in this release are presented in both Chinese Renminbi (RMB), as the Company's shares are traded on the Shenzhen Stock Exchange, as well as in United States dollars ($) as this is the major currency in which the Company's business is conducted. For the purposes of this release, a customary convenience translation has been used for the translation from RMB to US dollars, with Income Statement and Cash Flow items being translated using the quarterly average exchange rate, and Balance Sheet items being translated using the exchange rate at the end of the period.

      The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated.

      Note 2: Abridged Financial Statements

      For ease of use, the financial statements shown in this release have been abridged as follows:

      Abridged Consolidated Income Statement:

      • "Gross profit" in this release is revenue less costs of goods sold, taxes and surcharges, inventory impairment and other idleness charges (in addition to those already included in costs of goods sold); part of the idleness charges is removed in the Adjusted financial statements
      • "Other operating expenses" includes impairment losses (not including inventory impairment); gain (loss) from disposal of assets and non-operating income and expenses
      • "Operating expenses" in this release differ from those in the formally reported financial statements in that in the reported financial statements, as a result of recent changes in the ASBE guidelines (IAS 37), certain items as of Q4 2021 (specifically certain transportation costs and certain idleness charges) have been reclassified from Operating Expenses to COGS.
      • "Financial expenses and investment income" includes net financing expenses; gains from changes in fair value; and investment income (including share of income of equity accounted investees)

      Abridged Consolidated Balance Sheet:

      • "Other current assets, receivables and prepaid expenses" includes financial assets held for trading; financial assets in respect of derivatives; prepayments; other receivables; and other current assets
      • "Fixed assets, net" includes fixed assets and construction in progress
      • "Intangible assets, net" includes intangible assets and goodwill
      • "Other non-current assets" includes other equity investments; long-term equity investments; long-term receivables; investment property; and other non-current assets
      • "Loans and credit from banks and other lenders" includes short-term loans and non-current liabilities due within one year
      • "Other current liabilities" includes financial liabilities in respect of derivatives; payables for employee benefits, taxes, interest, dividends and others; advances from customers and other current liabilities
      • "Other long-term liabilities" includes long-term payables, provisions, deferred income and other non-current liabilities

      Income Statement Adjustments


      Q2 2022

      USD (m)

      Q2 2021

      USD (m)

      Q2 2022

      RMB (m)

      Q2 2021

      RMB (m)

      Net Income (Reported)

      46.1

      33.8

      304.4

      218.4

      Adjustments to COGS & Operating Expenses:





      1.  Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash)

      0.3

      0.3

      1.7

      1.6

      2.  Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash)

      5.7

      6.7

      37.5

      43.2

      3.  Upgrade & Relocation related costs

      2.0

      24.8

      13.3

      160.3

      4.  Incentive plans

      14.3

      (0.6)

      94.2

      (3.9)

      5.  Amortization of acquisition-related PPA (non-cash), other acquisition-related costs

      5.0

      3.8

      33.1

      24.4

      6.  Transportation classification COGS impact

      (46.6)

      -

      (308.1)

      -

      7.  Transportation classification OPEX impact

      46.6

      -

      308.1

      -

      Total Adjustments to Operating Income (EBIT)

      27.2

      34.9

      179.8

      225.6

      Total Adjustments to EBITDA

      15.9

      21.4

      105.3

      138.4

      Adjustments to Financing Expenses





      Revaluation of non-cash adjustment related to non-controlling interest

      3.6

      -

      23.8

      -

      Adjustments to Taxes





      1.  Tax shield on Legacy PPA of 2011 acquisition of Solutions

      0.0

      0.0

      0.3

      0.3

      3.  Taxes related to Upgrade & Relocation related costs

      0.1

      4.3

      0.4

      27.8

      5.  Deferred tax on amortization of acquisition-related PPA, other acquisition-related costs

      0.9

      0.6

      6.0

      3.9

      Total adjustments to Net Income

      29.8

      30.0

      196.9

      193.7

      Net Income (Adjusted)

      75.9

      63.8

      501.3

      412.1

      Total adjustments to Net Income attributable to the shareholders of the Company

      29.8

      29.7

      196.9

      191.6


      H1 2022

      USD (m)

      H1 2021

      USD (m)

      H1 2022

      RMB (m)

      H1 2021

      RMB (m)

      Net Income (Reported)

      113.5

      57.1

      732.1

      369.2

      Adjustments to COGS & Operating Expenses:





      1.  Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash)

      0.5

      0.5

      3.2

      3.2

      2.  Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash)

      11.3

      14.5

      73.2

      93.9

      3.  Upgrade & Relocation related costs

      3.9

      40.2

      25.3

      260.1

      4.  Incentive plans

      10.1

      3.5

      68.0

      22.9

      5.  Amortization of acquisition-related PPA (non-cash), other acquisition-related costs

      10.1

      7.5

      65.5

      48.7

      6.  Transportation classification COGS impact

      97.5

      -

      631.3

      -

      7.  Transportation classification OPEX impact

      (97.5)

      -

      (631.3)

      -

      8.  Provisions in respect of prior years' legal- and tax-related costs

      -

      1.6

      -

      10.3

      Total Adjustments to Operating Income (EBIT)

      35.9

      67.9

      235.3

      439.2

      Total Adjustments to EBITDA

      13.5

      40.8

      90.0

      263.9

      Adjustments to Financing Expenses





      Revaluation of non-cash adjustment related to non-controlling interest

      3.6

      -

      23.8

      -

      Adjustments to Taxes





      1.  Tax shield on Legacy PPA of 2011 acquisition of Solutions

      0.1

      0.1

      0.6

      0.5

      3.  Taxes related to Upgrade & Relocation related costs

      0.1

      6.7

      0.9

      43.3

      5.  Deferred tax on amortization of acquisition-related PPA, other acquisition-related costs

      1.8

      1.2

      11.8

      7.7

      8.   Provisions in tax expenses in respect of prior years' legal- and tax-related costs

      -

      0.4

      -

      2.5

      Total adjustments to Net Income

      37.5

      59.5

      245.8

      385.2

      Net Income (Adjusted)

      150.9

      116.6

      977.9

      754.4

      Total adjustments to Net Income attributable to the shareholders of the Company

      37.5

      58.7

      245.8

      380.1

      Notes:

      1. Amortization of Legacy PPA of 2011 acquisition of Solutions (non-cash): Under ASBE, since the first combined reporting for Q3 2017, the Company has inherited the historical "legacy" amortization charge that ChemChina previously was incurring in respect of its acquisition of Solutions in 2011. This amortization is done in a linear manner on a quarterly basis, most of which will have been completed by the end of 2020.
      2. Amortization of Transfer assets received and written-up due to 2017 ChemChina-Syngenta transaction (non-cash): The proceeds from the Divestment of crop protection products in connection with the approval by the EU Commission of the acquisition of Syngenta by ChemChina, net of taxes and transaction expenses, were paid to Syngenta in return for the transfer of a portfolio of products in Europe of similar nature and economic value. Since the products acquired from Syngenta are of the same nature and with the same net economic value as those divested, and since in 2018 the Company adjusted for the one-time gain that it made on the divested products, the additional amortization charge incurred due to the written-up value of the acquired assets is also adjusted to present a consistent view of Divestment and Transfer transactions, which had no net impact on the underlying economic performance of the Company. These additional amortization charges will continue until 2032 but at a reducing rate, yet will still be at a meaningful level until 2028.
      3. Upgrade & manufacturing facilities relocation-related costs: These charges all relate to the multi-year Upgrade & Relocation program in China. As part of this program, production assets located in the old production sites in Jingzhou and Huai'An were relocated to new sites in 2020, 2021 and in the coming years. Since some of the older production assets may not be able to be relocated, some of these assets which are no longer operational are being written off (or impaired), while for others, their economic life has been shortened and therefore will be depreciated over a shorter period. Since these are older assets that were built many years ago and will be replaced by newer production facilities at the new sites, and since the ongoing operations of the business will not be impacted thereby, the Company adjusts for the impact of all charges related to the China Upgrade & Relocated program, which include mainly: (i) excess procurement costs incurred as the Company continued to fulfill demand for its products, in order to protect its market position, through replacement sourcing at significantly higher costs from third-party suppliers (ii) elevated idleness charges largely related to suspensions at the facilities being relocated These charges have significantly declined since the first quarter of 2022, as the relocation and upgrade of the manufacturing Jingzhou site in China has been completed and is now at a high level of operation.
      4. Incentive plans: ADAMA granted certain of its employees, a long-term incentive (LTI) in the form of 'phantom' awards linked to the Company's share price. As such, the Company records an expense, or recognizes income, depending on the fluctuation in the Company's share price, regardless of award exercises. To neutralize the impact of such share price movements on the measurement of the Company's performance and expected employee compensation and to reflect the existing phantom awards, in the Company's adjusted financial performance, the LTI is presented on an equity-settled basis in accordance with the value of the existing plan at the grant date. During Q2 2022 the Company recorded expenses due to an increase in the Company's share price.
      5. Amortization of acquisition-related PPA (non-cash) and other acquisition-related costs: Related mainly to the non-cash amortization of intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions, with no impact on the ongoing performance of the companies acquired, as well as other M&A-related costs.
      6. Transportation classification COGS impact – as a result of recent changes in the ASBE guidelines [IAS 37], certain items as of Q4 2021 (specifically certain transportation costs and certain idleness charges) have been reclassified from Operating Expenses to COGS.
      7. Transportation classification OPEX impact – as a result of recent changes in the ASBE guidelines [IAS 37], certain items as of Q42021 (specifically certain transportation costs and certain idleness charges) have been reclassified from Operating Expenses to COGS.
      8. Provisions in tax expenses related to prior years' activities: Provisions in respect of tax expenses related to activities of prior years.

      Exchange Rate Data for the Company's Principal Functional Currencies


      June 30


      Q2 Average


      H1 Average

      2022

      2021

      Change


      2022

      2021

      Change


      2022

      2021

      Change

      EUR/USD

      1.040

      1.189

      (12.5 %)


      1.066

      1.20

      (11.4 %)


      1.094

      1.205

      (9.3 %)

      USD/BRL

      5.238

      5.002

      (4.7 %)


      4.921

      5.30

      7.1 %


      5.077

      5.384

      5.7 %

      USD/PLN

      4.483

      3.804

      (17.9 %)


      4.359

      3.76

      (15.8 %)


      4.239

      3.768

      (12.5 %)

      USD/ZAR

      16.103

      14.347

      (12.2 %)


      15.570

      14.12

      (10.3 %)


      15.409

      14.545

      (5.9 %)

      AUD/USD

      0.687

      0.750

      (8.4 %)


      0.716

      0.77

      (7.0 %)


      0.720

      0.771

      (6.7 %)

      GBP/USD

      1.211

      1.386

      (12.6 %)


      1.211

      1.40

      (13.3 %)


      1.299

      1.388

      (6.5 %)

      USD/ILS

      3.500

      3.260

      (7.4 %)


      3.500

      3.27

      (7.9 %)


      3.270

      3.268

      (0.1 %)

      USD LIBOR 3M

      2.29 %

      0.15 %

      1468.4 %


      1.53 %

      0.16 %

      884.6 %


      1.03 %

      0.18 %

      476.0 %


      June 30


      Q2 Average


      H1 Average

      2022

      2021

      Change


      2022

      2021

      Change


      2022

      2021

      Change

      USD/RMB

      6.711

      6.460

      3.9 %


      6.611

      6.458

      2.4 %


      6.481

      6.470

      0.2 %

      EUR/RMB

      6.977

      7.678

      (9.1 %)


      7.051

      7.776

      (9.3 %)


      7.088

      7.797

      (9.1 %)

      RMB/BRL

      0.780

      0.774

      (0.8 %)


      0.744

      0.820

      9.2 %


      0.783

      0.832

      5.9 %

      RMB/PLN

      0.668

      0.589

      (13.4 %)


      0.659

      0.583

      (13.2 %)


      0.654

      0.582

      (12.3 %)

      RMB/ZAR

      0.417

      0.450

      7.4 %


      0.425

      0.457

      7.2 %


      0.421

      0.445

      5.4 %

      AUD/RMB

      4.613

      4.845

      (4.8 %)


      4.731

      4.967

      (4.7 %)


      4.663

      4.989

      (6.5 %)

      GBP/RMB

      8.125

      8.952

      (9.2 %)


      8.318

      9.022

      (7.8 %)


      8.416

      8.982

      (6.3 %)

      RMB/ILS

      0.522

      0.505

      (3.3 %)


      0.505

      0.506

      0.0 %


      0.505

      0.505

      0.1 %

      RMB LIBOR 3M

      2.000 %

      2.46 %

      (18.6 %)


      2.139 %

      2.524 %

      (15.3 %)


      2.276 %

      2.617 %

      (13.0 %)

      [1] CER: Constant Exchange Rates

      [2] Sources: Agbio Investor; Rabobank, ACMR monthly June 2022; Morgan Stanley, Freight Transportation, June 2022; JP Morgan Agricultural Markets Weekly, June 2022

      [3]  Despite not having received yet full label registration in Germany, Folpet was granted "Nationwide emergency registration for FOLPAN® 500 SC against Ramularia collo-cygni in barley" allowing it to be used only for this specification.

      [4] For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the financial statements, see below "Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements".

      [5] The number of shares used to calculate both basic and diluted earnings per share in Q2 2021 and Q2 2022 is 2,329.8 million shares.

      [6] For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the financial statements, see below "Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements".

      [7] The number of shares used to calculate both basic and diluted earnings per share in H1 2021 and H1 2022 is 2,329.8 million shares.

      SOURCE ADAMA Ltd.

      Modal title

      Also from this source

      ADAMA Reports Third Quarter & First Nine Months 2026 Results

      ADAMA Reports Third Quarter & First Nine Months 2026 Results

      ADAMA Ltd. (the "Company") (SZSE: 000553), today reported its financial results for the third quarter & first nine-months ended September 30, 2026....

      ADAMA Launches Botanical Fungicide Actavan® in Australia and New Zealand

      ADAMA Launches Botanical Fungicide Actavan® in Australia and New Zealand

      ADAMA Ltd. (SZSE: 000553), a leading global crop protection company, announced the launch of Actavan® in Australia and New Zealand, a plant-based...

      More Releases From This Source

      Explore

      Agriculture

      Agriculture

      Banking & Financial Services

      Banking & Financial Services

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.